Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/121106
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Evaluation of the ResistancePlus GC (beta) assay: a commercial diagnostic test for the direct detection of ciprofloxacin susceptibility or resistance in Neisseria gonorrhoeae |
Author: | Ebeyan, S. Windsor, M. Bordin, A. Mhango, L. Erskine, S. Trembizki, E. Mokany, E. Tan, L.Y. Whiley, D. Guy, R. Guy, R. Wand, H. Donovan, B. Bell, S. Kaldor, J. Kong, M. Conway, D. Lafferty, L. Ward, J. Lahra, M. et al. |
Citation: | Journal of Antimicrobial Chemotherapy, 2019; 74(7):1820-1824 |
Publisher: | Oxford University Press |
Issue Date: | 2019 |
ISSN: | 0305-7453 1460-2091 |
Statement of Responsibility: | Samantha Ebeyan, Madeline Windsor, Amanda Bordin, Lebogang Mhango, Simon Erskine, Ella Trembizki, Elisa Mokany, Lit Yeen Tan and David Whiley on behalf of the GRAND2 Study Investigators |
Abstract: | Objectives: To evaluate the performance of the ResistancePlus GC (beta) assay for the simultaneous detection of Neisseria gonorrhoeae and gyrA S91 markers of resistance (S91F) and susceptibility (WT) to ciprofloxacin, from both clinical specimens and isolates. Methods: Performance was assessed on several sample banks, including N. gonorrhoeae isolates (n"822), nongonococcal isolates (n"110), N. gonorrhoeae-positive clinical specimens (n"402) and N. gonorrhoeae-negative specimens (n"290). Results were compared with previous testing data, including S91 genotyping and phenotypic resistance profiles. Results: Overall, the assay demonstrated 100% sensitivity for N. gonorrhoeae detection in clinical isolates. For gyrA S91 mutation detection in clinical isolates, the assay showed 100% sensitivity/specificity compared with the genotype, and .99%/>97% sensitivity/specificity when compared with phenotype. For positive clinical specimens, the assay demonstrated .96% sensitivity for N. gonorrhoeae detection and 100% sensitivity/specificity for gyrA S91 mutation detection. The assay demonstrated .99% specificity for N. gonorrhoeae detection against non-gonococcal isolates and 100% specificity for negative clinical specimens. Conclusions: The ResistancePlus GC (beta) assay is suitable for the detection of N. gonorrhoeae and gyrA markers associated with resistance/susceptibility to ciprofloxacin directly in clinical samples. This assay could be implemented for the individualized treatment of gonorrhoea infections as well as to enhance current antimicrobial resistance surveillance methods. |
Keywords: | GRAND2 Study Investigators Humans Neisseria gonorrhoeae Gonorrhea Ciprofloxacin DNA Gyrase Anti-Bacterial Agents Microbial Sensitivity Tests Sensitivity and Specificity Drug Resistance, Bacterial Genotype Female Male Genotyping Techniques |
Rights: | © The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. |
DOI: | 10.1093/jac/dkz108 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/01122141 |
Published version: | http://dx.doi.org/10.1093/jac/dkz108 |
Appears in Collections: | Aurora harvest 8 Pharmacology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.